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ABSTRACT
Objective We performed a randomised trial in very
preterm, small for gestational age (SGA) babies to
determine if prophylaxis with granulocyte macrophage
colony stimulating factor (GM-CSF) improves outcomes
(the PROGRAMS trial). GM-CSF was associated with
improved neonatal neutrophil counts, but no change in
other neonatal or 2-year outcomes. As subtle beneﬁts in
outcome may not be ascertainable until school age we
performed an outcome study at 5 years.
Patients and methods 280 babies born at 31 weeks
of gestation or less and SGA were entered into the trial.
Outcomes were assessed at 5 years to determine
neurodevelopmental and general health status and
educational attainment.
Results We found no signiﬁcant differences in
cognitive, general health or educational outcomes
between 83 of 106 (78%) surviving children in the GM-
CSF arm compared with 81 of 110 (74%) in the control
arm. Mean mental processing composite (equivalent to
IQ) at 5 years were 94 (SD 16) compared with 95
(SD 15), respectively (difference in means −1 (95%CI −6
to 4), and similar proportions were in receipt of special
educational needs support (41% vs 35%; risk ratio 1.2
(95% CI 0.8 to 1.9)). Performance on Kaufmann-ABC
subscales and components of NEPSY were similar. The
suggestion of worse respiratory outcomes in the GM-CSF
group at 2 years was replicated at 5 years.
Conclusions The administration of GM-CSF to very
preterm SGA babies is not associated with improved or
more adverse neurodevelopmental, general health or
educational outcomes at 5 years.
Trial registration number ISRCTN42553489.
INTRODUCTION
Perinatal infection and inﬂammation have been
implicated in the causal pathway of neonatal
preterm brain injury and deviations from normal
neurodevelopmental patterns.1 2 Many develop-
mental problems, such as learning difﬁculty, poor
general and executive cognitive processes and
behavioural disorders, are not easily determined
until early school age. Interventions targeted at
reducing the inﬂammatory load during the neonatal
period may therefore not demonstrate beneﬁt until
such functions are measureable.
Very preterm babies with fetal growth restriction,
who are born small for gestational age (SGA), are at
high risk of developing acquired sepsis after
birth and this has been believed to relate to the fre-
quent observation of neutropenia in such babies.
Granulocyte macrophage colony stimulating factor
(GM-CSF) has been shown to be effective at redu-
cing neutropenia-related infections in patients with
cancer after chemotherapy.3 In order to study the
potential beneﬁts of GM-CSF in preterm growth-
restricted infants, we undertook PROGRAMS, a
single blind, multicentre, randomised trial of
GM-CSF in very preterm SGA babies, to determine
whether treatment resulted in a reduced incidence
of infection, mortality and morbidity in the neonatal
period and over the longer term. Two hundred and
eighty newborn SGA infants of 31 completed weeks
gestational age or less were randomly allocated to
GM-CSF or routine treatment within 72 h of birth.
Although neutrophil counts were signiﬁcantly
higher in GM-CSF treated babies, there was no sig-
niﬁcant difference in sepsis-free survival at 14 days
from trial entry between the two treatment arms,4
in keeping with the ﬁndings of our updated system-
atic review,5 and no beneﬁt was demonstrated in
terms of developmental outcomes at 2 years of age
adjusted for prematurity.6 However, we observed a
larger proportion of children with developmental
impairment than was consistent with the degree of
prematurity and speculated that intrauterine growth
restriction placed these children at particular devel-
opmental risk.
As part of the original design of the trial, we
hypothesised that there might be more subtle
What is already known on this topic?
▸ Neonatal neutropenia and sepsis are common
following fetal growth restriction.
▸ Administration of granulocyte macrophage
colony stimulating factor (GM-CSF) after birth
raises neutrophil counts but does not improve
neonatal or 2-year developmental outcomes.
What this study adds?
▸ Granulocyte macrophage colony stimulating
factor (GM-CSF) administered after birth does
not alter 5-year neurocognitive outcomes.
▸ Preterm small-for-gestational-age (SGA) babies
have a higher prevalence of special educational
needs than anticipated from their gestational
age at birth.
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beneﬁts over and above the relatively short-term developmental
outcomes described above and therefore designed an outcome
evaluation at 5 years of age to determine whether the adminis-
tration of GM-CSF in the neonatal period was associated with
differences in the prevalence of developmental problems.
METHODS
Full details of the PROGRAMS trial4 and 2-year follow up6
have been published. Brieﬂy, participants were infants born at
≤31 completed weeks of gestation with birth weight <10th
centile (UK 1990 Growth Reference). An infant was not eligible
if there was an immediately life-threatening congenital abnor-
mality, or a strong likelihood of early onset sepsis, indicated by
maternal pyrexia exceeding 38°C on two occasions during
labour. The study intervention, GM-CSF, was given in a dose of
10 mg/kg subcutaneously daily for ﬁve consecutive days. No
placebo injections were administered to the standard treatment
arm of the study. Two commercial preparations of recombinant
human GM-CSF were used during the study, molgramostim
(Leucomax, Novartis, UK), and sargramostim (Leukine, Berlex,
California, USA), which have equivalent biological potency for
stimulating granulocyte production and function, in vitro and in
vivo. Consistent with this, neutrophil counts were signiﬁcantly
higher in the treatment arm. At 2 years of age 94% of surviving
children were evaluated.
FIVE-YEAR OUTCOME EVALUATION
Contact was maintained with the families enrolled in the study
following the 2-year evaluation; parents were informed of the
results of the trial and follow-up study by newsletter. As previ-
ously, the children were traced and the families contacted by the
study coordinator. Parents were asked for permission to carry
out the evaluation at 5 years and to provide details of their
child’s school. Head teachers were then approached and a
request made for a member of the study team to visit the school
and carry out the testing. Parents were invited to attend as they
wished. The assessment was carried out as close to the child’s
5th birthday as feasible and no adjustment was made for gesta-
tional age at birth. Where a child was in a special school with
serious disability, a formal assessment by a paediatrician and
estimate of learning attainment was made. Details of school
attainment and need for extra educational support (‘special
needs’) were provided by the child’s class teacher, who also
completed the teacher’s report for the Strengths and Difﬁculties
Questionnaire (SDQ, http://www.sdqinfo.com) to evaluate
behaviour at school.
Psychologists were trained and validated in the study evalua-
tions. Children were assessed in school and the assessors
masked to group assignment.
The primary outcome measure was general intelligence as
measured using the mental processing composite (MPC; equiva-
lent to IQ) of the Kaufmann-ABC (Pearson UK).7 The MPC and
subscales were originally normed to a mean of 100 and a SD of
15 in the general population. The subscales used were simultan-
eous processing, sequential processing, maths and riddles.
Executive functions were evaluated using components from
NEPSY (Pearson, UK)8 in the domains of sensorimotor, visuo-
spatial, attention-executive, language and memory/learning.
Scaled scores taken from normative data were compared
between trial groups. Behaviour was evaluated using parent and
teacher report forms from the SDQ, generating overall scores
(assessed against population norms to generate the proportion
with disorder) and subscale scores for emotional symptoms,
conduct problems, hyperactivity-inattention, peer problems and
(for teachers’ report) school adaptation. Height, weight and
head circumference were measured by the assessor using stand-
ard techniques (Leicester Height Measure (Seca), Scales (Salter
Model 918) and Lass-O tapes (Child Growth Foundation)), and
referred to UK-WHO Child Standards.9
In addition to the SDQ, parents also completed question-
naires detailing household socioeconomic status, and the lan-
guage and communication element of the 4-year evaluation
from the Twins and Early Development Study,10 hospitalisations
since 2 years and a proﬁle of respiratory symptoms and treat-
ment derived from the ISAACS questionnaire.11
STATISTICAL METHODS
The sample size for the initial study was based on the short-term
primary outcome, survival without sepsis for 14 days from trial
entry.4
A CONSORT diagram was constructed, showing the ﬂow of
participants through the study.12 Variables were summarised as
number (per cent) or median (25th–75th centile) for categorical
or continuous/ranked data, respectively (none of the continuous
variables approached approximate normality). For analysis of
outcomes, relative risks were used to quantify the effect of treat-
ment on categorical variables. Median differences between treat-
ment groups were calculated for continuous and ranked data;
95% CIs were calculated to quantify uncertainty about relative
risks and median differences.13
All analyses were conducted on an intention-to-treat basis,
that is, participants were never excluded from analyses on the
basis of the treatment received. The participants lost to
follow-up or withdrawn were not included in analyses.
STUDY MANAGEMENT
Written informed consent was obtained from parents. Trial over-
sight was provided by an independent steering committee
and independent data monitoring and ethics committee. This
study is registered as an International Standard Randomised
Controlled Trial, number ISRCTN42553489.
Figure 1 Consort diagram for the PROGRAMS study. GM-CSF,
granulocyte macrophage colony stimulating factor.
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RESULTS
Of 280 babies enrolled in the study, 279 completed the study
intervention, 64 babies died (62 before and 2 after neonatal dis-
charge), 11 were withdrawn by their parents and a further 41
families were lost to follow-up at 5 years. Details of the partici-
pant ﬂow through the study are shown in ﬁgure 1. In the
GM-CSF arm, 83 children were evaluated at a median of
65 months (range 50–78) and 81 in the control arm at a median
of 65 months (52–78). There were no signiﬁcant or systematic
differences between those who were included and those who
dropped out of the study over a range of infant and maternal
characteristics at trial entry or short-term neonatal outcomes
(see web table S1).
In those who were followed up, the two study groups were
balanced over a range of social and demographic measures (see
web tables S2 and S3). The index of multiple deprivation score14
for each family showed a median value of 19 (IQR: 10, 31) for
families in the GM-CSF arm compared with 19 (IQR: 10, 34) in
the control arm.
Primary outcome: Kaufmann MPC scores for the GM-CSF
group were 94 (SD 16) compared with 95 (SD 15) in controls,
difference in means: −1 (95%CI −6 to 4). Subscale scores did
not vary signiﬁcantly between groups and the proportion scoring
−2 SD or lower (<70) or between −1 and −2SD were similar
(table 1). There were no signiﬁcant differences across NEPSY
scaled scores (table 1), and no signiﬁcant differences in behav-
ioural scores (table 2), nor in parent reported language and com-
munication skills (table 3), between the two arms. In the
GM-CSF and control groups, and despite mean IQ scores of 95,
a large but similar proportion of each trial group were in receipt
of special needs support (41% and 35%, respectively), statements
of educational needs (17% vs 13%), and had met Key Stage 1
national attainment levels (table 4). Growth measures, expressed
as Z or SD scores, were similar between the two groups (table 5).
Fewer families returned health questionnaires than the
number of children who were assessed at school: 62 in the
GM-CSF group and 54 in the control group (see web table S4).
Admissions to hospital were infrequent in both groups and no
Table 1 Measured cognitive outcomes for children exposed to GM-CSF compared with control children in the PROGRAMS trial groups at
5 years of age
GM-CSF (n=79) Control (n=78)
Mean or no/total % or SD Mean or no/total % or SD Difference in means (95% CI)
Cognitive development
Kaufmann ABC
Mental processing composite 94 (16) 95 (15) −1 (−6 to 4)
<70 4/78 5% 2/77 3%
70–85 9/78 12% 18/77 23%
Simultaneous processing 95 (17) 95 (16) 0 (−5 to 5)
<70 6/78 8% 2 3%
70–85 10/78 13% 20 26%
Sequential processing 94 (19) 98 (14) −3 (−8 to 2)
<70 7/78 9% 2 3%
70–85 4/78 5% 13 17%
Maths score 99 (14) 97 (13) 1 (−3 to 5)
<70 3/78 4% 5 6%
70–85 8/78 10% 10 13%
Riddles 94 (14) 93 (13) 1 (−3 to 5)
<70 5/76 7% 2/77 3%
70–85 11/76 14% 18/77 23%
Neuropsychological assessment (NEPSY) Median (IQR) Median (IQR) Difference in medians (95% CI)
Sensorimotor component scaled scores
Imitating hand positions 7 5, 8 7 5, 9 −0.2 (−1.1 to 0.8)
Visuomotor precision 6 4, 9 7 5, 8 −0.4 (−1.5 to 0.6)
Visuospatial component scaled score (2 of 4)
Block construction 8 7, 10 8 5, 10 0.9 (−1.6 to 3.5)
Design copying 8 6, 10 8 6, 10 0.1 (−0.9 to 1.1)
Attention executive component (2 of 6)
Visual attention scaled score 10 8, 12 10 8, 12 0.1 (−3.3 to 3.5)
Statue total score 23 14, 27 23 12, 27 −0.2 (−4.1 to 4.1)
Language component scaled score (2 of 7)
Phonological processing 8 7, 10 9 6, 10 0.3 (−0.9 to 1.4)
Comprehension of instructions 10 8, 12 10 8, 11 −0.9 (−3.5 to 1.6)
Memory and learning component scaled score (4 of 5)
Delayed memory for faces 9 5, 13 10 4, 12 0.1 (−1.2 to 1.9)
Narrative memory 8 6, 10 8 6, 10 0.3 (−0.8 to 1.4)
Delayed memory for names 7 2, 9 8 3, 10 −1.1 (−2.5 to 0.23)
Sentence repetition 9 7, 11 9 7, 11 0.9 (−1.6 to 3.4)
GM-CSF, granulocyte macrophage colony stimulating factor.
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child was admitted to an intensive care unit and mechanically
ventilated. At 5 years the point prevalence of cough and wheeze
were higher and the use of respiratory medications more fre-
quent in the GM-CSF group (with relative risk values of 1.7–2
for most comparisons, web table S5), but none of the compari-
sons would be statistically signiﬁcant if adjusted for multiple
comparisons.
DISCUSSION
This is the ﬁrst report of childhood outcomes at 5 years of age
following the neonatal administration of GM-CSF to SGA very
preterm babies in a randomised trial. We have previously
reported that GM-CSF raises neonatal neutrophil counts, but
does not appear to reduce the prevalence of neonatal sepsis or
other neonatal morbidities; nor affect neurodevelopment at
2 years of age adjusted for prematurity.6 Here we show that it
does not affect neuropsychological outcomes at 5 years. In con-
trast to the neonatal ﬁndings of marginally worse respiratory
outcomes in the control babies, follow-up at 2 years and 5 years
seems to indicate marginally worse respiratory outcomes among
the GM-CSF treated infants though these differences were not
statistically signiﬁcant.
For the 5-year outcomes we achieved reasonable follow-up
rates of 76%. Surviving children who were not evaluated did not
Table 2 Behaviour scores from the Strengths and Difficulties Questionnaire for children exposed to GM-CSF compared with control children in
the PROGRAMS trial groups at 5 years
GM-CSF
Control Difference in medians (95% CI)Median (IQR)
Parent SDQ (n=62) (n=54)
Emotional disorder score (max. 15) 6 (6, 7) 6 (5, 7) 0 (0 to 1)
Disorder n (%) 0 (0%) 0 (0%)
Conduct disorder score (max 15) 5 (5, 5) 5 (5, 6) 0 (0 to 0)
Disorder n (%) 0 (0%) 1 (2%)
Hyperactivity disorder score (max 15) 5 (4, 6) 5 (4, 6) 0 (0 to 1)
Disorder n (%) 40 (65%) 38 (70%)
Peer relationships score (max 15) 5 (5, 7) 5 (5, 7) 0 (0 to 0)
Disorder n (%) 1 (2%) 2 (4%)
Overall score (max 60) 23 (20, 25) 21 (19, 24) 1.0 (−0.3 to 2.2)
Disorder n (%) 0 (0%) 0 (0%)
Teacher SDQ (n=73) (n=70)
Emotional disorder score (max. 15) 6 (5, 7) 6 (5, 8) 0 (0 to 0)
Disorder n (%) 0 (0%) 0 (0%)
Conduct disorder score (max 15) 5 (4, 5) 5 (5, 5) 0 (0 to 0)
Disorder n (%) 0 (0%) 0 (0%)
Hyperactivity disorder score (max. 15) 5 (4, 6) 5 (4, 6) 0 (-1 to 0)
Disorder n (%) 40 (55%) 34 (49%)
Peer relationships score (max 15) 5 (4, 5) 5 (4, 5) 0 (0 to 0)
Disorder n (%) 10 (14%) 2 (3%)
Overall score (max 60) 21 (19 to 23) 21 (20 to 23) −0.5 (−1.4 to 0.5)
Disorder n (%) 0 (0%) 0 (0%)
School adaptation (impact) 3 (2, 4) 3 (2, 4) 0 (0 to 1)
‘Disorder’ indicates the number of children with borderline or clinical scores compared with reference data.
GM-CSF, granulocyte macrophage colony stimulating factor; SDQ, Strengths and Difficulties Questionnaire.
Table 3 Scales derived from the Twins and Early Development Study (TEDS) measures at 4 years applied to the children exposed to GM-CSF
compared with control children in PROGRAMS trial groups at 5 years of age
GM-CSF (n=62) Control (n=54)
Outcome Max score No or median % or IQR No or median % or IQR
Your child’s development
Talking (1–6), median (IQR) 6 6, 6 6 6, 6
Actions or words—n% with actions 3/61 5% 3 6%
Sounds younger—n% 17 27% 8 15%
Your child’s words (total n) 48 41 29, 46 41 33, 48
Using language (total ‘yes’ responses) 14 12 7, 13 13 11, 14
Books (total ‘yes’ responses) 12 8 6, 9 8 6, 9
Communication worries n (%) 23 37% 14 26%
Professional advice n (%) 32 52% 24 44%
Communication score, median (IQR) 30 26 22, 26 26 24, 27
Total ‘TEDS’ score, median (IQR) 94 85 66, 93 86 80, 93
GM-CSF, granulocyte macrophage colony stimulating factor.
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Table 4 School attainment for children exposed to GM-CSF compared with control children in PROGRAMS trial groups at 5 years of age
GM-CSF (n=73) Control (n=70) Risk ratio (95% CI)
Special educational needs
Academic 29/69 (42%) 24/65 (37%) 1.1 (0.7 to 1.7)
Behavioural 16/71 (23%) 11/61 (18%) 1.3 (0.6 to 2.5)
Statement (yes/no)* 12/72 (17%) 9/68 (13%) 1.3 (0.6 to 2.8)
On register (England only)† 26/67 (39%) 22/66 (33%) 1.2 (0.7 to 1.8)
Stage 1 1 2
Stage 2 2 1
Stage 3 1 2
Stage 4/5 6 3
Special needs support (yes/no) 31 (41%) 24/69 (35%) 1.2 (0.8 to 1.9)
Individual special needs plan 23 21
One-to-one provision 15 6
Small group provision 20 18
Outreach teachers 5 3
Educational psychologist 8 4
Clinical psychologist 1 1
Physiotherapist 2 5
Speech/language therapist 12 14
Requires additional support (yes/no)‡ 19/71 (27%) 21 (30%) 0.9 (0.5 to 1.5)
Individual special needs plan 7 10
One-to-one provision 8 10
Small group provision 6 10
Outreach teachers 1 2
Educational psychologist 0 5
Clinical psychologist 0 1
Physiotherapist 2 1
Speech/language therapist 4 9
Key stage attainment Median grade (IQR) Difference in medians (95% CI)
English
Speaking and listening 3 (3, 4) 3 (3, 4) 0 (0 to 1)
Reading 3 (3, 4) 3 (3, 4) 0 (0 to 0)
Writing 4 (3, 5) 3 (3, 4) 0 (0 to 1)
Spelling 3 (3, 5) 3 (3, 4) 0 (0 to 1)
Maths
Using and applying 3 (3, 4) 3 (3, 4) 0 (0 to 0)
Numbers and algebra 3 (3, 4) 3 (3, 4) 0 (0 to 1)
Shape, space and measures 3 (3, 4) 3 (3, 4) 0 (0 to 0)
*Formal binding statutory educational statement of needs.
†Indicates progress through the statement process.
‡Teacher assessed need for support not provided.
GM-CSF, granulocyte macrophage colony stimulating factor.
Table 5 Growth at 5 years for children exposed to GM-CSF compared with control children in PROGRAMS trial groups at 5 years of age
Mean (SD)
GM-CSF (n=60) Control (n=61) Difference in medians (95% CI)
Height
cm 104 (10) 105 (9) −0.9 (−4.4 to 2.7)
SDS* −1.7 (2.4) −1.6 (2.1) −0.1 (−0.9 to 0.7)
Weight
kg 17 (3) 17 (3) 0.3 (−0.7 to 1.3)
SDS* −1.1 (1.3) −1.3 (1.3) 0.2 (−0.3 to 0.6)
Head circumference
cm 50 (2) 50 (2) 0 (−1 to 1)
SDS* −1.7 (1.4) −1.9 (1.3) 0.2 (−0.3 to 0.7)
*Height, weight, head circumference SD scores from UK-WHO standards.
GM-CSF, granulocyte macrophage colony stimulating factor.
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differ over a range of perinatal and neonatal variables from chil-
dren evaluated as part of this study. Nonetheless children who
are not available for follow-up may have higher rates of impair-
ment compared with those evaluated,15 16 which may bias the
results. We chose not to correct for preterm birth in calculating
the age at assessment, as this is conventional at this age. The ges-
tational age distributions were well balanced between the two
groups and it would have been unlikely to alter the ﬁndings.
We chose a wide range of neuropsychological tests from
direct observation, parents and teachers to make a comprehen-
sive assessment. Furthermore we obtained summary functional
information concerning educational attainment to conﬁrm the
results of our testing. Although the general cognitive scores
appear only mildly depressed compared with standardisation
data (5–6 points or approximately 0.33 SD), the test used was
standardised in the late 1970s.7 The results of population
testing of IQ tend to rise over time;17 using the original test the
classmate comparison group used in the EPICure study at
6 years in 2001–2002 produced mean scores of 107 (SD 12) in
term-born children.18 Hence the PROGRAMS group scores rep-
resent approximately −1 SD (13–14 points) below the mean at
best, which is consistent with population estimates of scores in
very preterm children. This is also in keeping with the teachers’
reports that 39% of the PROGRAMS group was receiving
special educational support and 15% had an educational state-
ment of needs in the 1st year of schooling.
In the absence of a comparison group of babies born at full
term it is difﬁcult to evaluate the performance of this group of
SGA children relative to other very preterm groups. The major-
ity of children in this study had fetal growth restriction. In a
prospective cohort study of children identiﬁed before birth with
growth restriction, scores at 6 years were on average 11 points
lower compared with AGA-matched children, whose IQ scores
were 12 points lower than term-born children.19 At 2 years of
age adjusted for prematurity Bayley MDI (BSID-II) scores for
the PROGRAMS cohort were lower than expected considering
their gestational age at birth and scores were similar to those
from our national cohort of babies born before 26 weeks of ges-
tation (EPICure).20 At the 5-year assessment the scores using the
same test appear higher, suggesting some catch up by the
PROGRAMS group. However, in comparison to national data
from Scotland, where the proportion with special educational
needs among very preterm survivors rises from 12% for those
born at 30 weeks gestation to around 30% for those born at
26 weeks gestation,21 the rate of 39% reported in this study
seems high. It seems likely that SGA very preterm children have
higher rates of cognitive and learning problems than their
appropriately grown peers. Thus, it is important to identify very
preterm children to teachers for close assessment of their needs.
The persistence of the trend for increased risk of respiratory
symptoms is intriguing. Cohort studies associate bronchopul-
monary dysplasia with perinatal infection22 and fetal growth
restriction.23 Further the associations between measured inﬂam-
matory mediators and bronchopulmonary dysplasia or develop-
mental outcomes seem particularly strong when these mediators
are elevated postnatally,24 over the same period as when
GM-CSF was administered in this study. Nonetheless we found
these ﬁndings difﬁcult to explain at 2 years. We did not collect
information on family smoking status, which may have
accounted for this difference. The inconsistency between out-
comes at discharge, and at 2 years and 5 years suggests these
ﬁndings may have arisen by chance.
Prior to the clinical use of G-CSF and GM-CSF in newborn
babies during the 1990s, concern was raised that exposure of
the immature haematopoietic and immune system to pharmaco-
logical doses of these recombinant human cytokines might lead
to later alternations to haematopoiesis, immune function, or
drive the emergence of malignant clones and leukaemia.25
Follow-up of an early G-CSF study in neonates found no alter-
ation in routine haematological or biochemical parameters at
2 years of age;26 there have been no cases of leukaemia in the
PROGRAMS cohort, and the equivalent number of non-surgical
admission to hospital between groups (see web table S4). These
observations provide no evidence to suggest altered defence
against bacterial or viral infection. Safety is further supported by
the now extensive experience of long-term use of CSF therapy
in children with cyclical neutropenia.27
CONCLUSIONS
When evaluated in a randomised trial, with long-term follow-up
at 2 years and 5 years of age, GM-CSF does not appear to offer
signiﬁcant beneﬁt in terms of neuroprotection.
Twitter Follow Timothy Morris at @tmorris_mrc
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